glp-1 receptor agonists in idiopathic intracranial hypertension The effect of agonist on hypertension: a systematic review and meta-analysis Efficacy of glucagon-like peptide-1 receptor
Description
JL: Data curation, Methodology, Writing original draft
Following the massive success of WEGOVY (semaglutide 2.4 mg), the company is evaluating semaglutide 7.2 mg in phase III obesity drug clinical trials
(2023) 46:S128S39
Nyakas C, Granic I, Halmy LG, Banerjee P, Luiten PG
In recent years, GLP-1 medications have become a focal point in the medical community due to their innovative treatment mechanisms, significant therapeutic efficacy, and broad development prospects
